@FiercePharma: Popular this morning on our website: Eli Lilly's $15B battle for longer Alimta monopoly hits court today. Story | Follow @FiercePharma
@CarlyHFierce: The gang at FierceBiotech is looking for 2013's fiercest women in biotech. Submit nominations here. | Follow @CarlyHFierce
> Hospira ($HSP) failed to convince a California judge to throw out claims by an ex-University of Southern California football player who suffered a heart attack after taking the company's painkiller Toradol. Report (sub. req.)
> Merck ($MRK) re-upped its contract manufacturing deal with Russian's Akrikhin to stay in line with the government's goals for domestic production of marketed drugs. Report
> Denmark's Lundbeck said that it had increased its share capital by 11,204 shares on warrants exercised by employees. Report
> Boehringer Ingelheim tapped the PR firm Pegasus to help promote its new irritable bowel treatment Buscopan in the U.K. Report
> Merck and the plaintiffs suing over jaw injuries allegedly caused by Fosamax are debating plans for the last phase of the multidistrict litigation. Report
> The multiple sclerosis market could hit $18.3 billion by 2018, Datamonitor analysts figure. Report
Medical Device News
@FierceMedDev: Covidien yanks syringes over sterility risk. Report | Follow @FierceMedDev
@DamianFierce: Introducing B-a-MedFounder, a new crowdfunding platform for medical devices. ICYM yesterday's popular story | Follow @DamianFierce
@MarkHFierce: Medtronic reported a double-digit increase in net earnings during Q1. Release | Follow @MarkHFierce
@MichaelGFierce: ICYMI: Platinum-based radiotherapy method zaps cancer with nanomeds. More from FierceDrugDelivery | Follow @MichaelGFierce
> Applied Proteomics lands $28M for diagnostics. Story
> Quest to sell Thermo Fisher's peanut allergy diagnostic. Item
> Boston Scientific eyes FDA with PAD stent. Article
> Bard grabs Medafor for $200M, diving deep into the blood-clotting business. Report
Biotech News
@FierceBiotech: ICYMI from FierceBiotechIT: Pfizer taps online marketplace for outsourcing research. Story | Follow @FierceBiotech
@JohnCFierce: I wonder if this will reignite some old rumors of a Novartis buyout for MorphoSys. I suspect so. Article | Follow @JohnCFierce
@RyanMFierce: Pfizer's social head touted some of the internal and external feats of the pharma giant. More | Follow @RyanMFierce
> Adimab adds Celgene to high-profile clientele for antibody drug discovery. News
> Regado has to slash IPO price to complete $42M raise. Report
> Eisai suit prods DEA for slow-motion drug classification roadblock. More
> Analyst urges Merck to overhaul its weak $8B R&D operation. Story
Pharma Manufacturing News
@EricPFierce: WSJ: Eisai sues DEA to get it to move on epilepsy drug Fycompa which FDA approved in October. FiercePharma story | Follow @EricPFierce
> FDA program would allow inspectors to focus on trouble spots. More
> Ben Venue trimming manufacturing, jobs at troubled plant. Story
> Zydus Cadila injects $160M into injectables. Report
> Coup de grâce for Boehringer Ingelheim Virginia plant. More
> Ukraine sentences drug counterfeiter to 4 years. Item
Biotech Research News
@EmilyMFierce: The latest at FierceBiotechResearch.com: Nerve cell death reversed in Parkinson's cells. Article | Follow @EmilyMFierce
> Industry-acade
> Diabetes progression slowed in mice. Story
> Inovio vaccine kills malaria, boosts immune response in animals. More
> Pluristem's stem cell therapy improves tendon injuries in rats. Item
> Seattle BioMed wins $16M NIH grant for TB research. Article
And Finally... A generic tuberculosis drug, isoniazid, could prevent tuberculosis in at-risk HIV patients, a study found. Report